Agile Therapeutics to Speak at Biotech 2011
CEO to Discuss Financing Strategies for Emerging Biotech Companies
(firmenpresse) - PRINCETON, NJ -- (Marketwire) -- 10/25/11 -- Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, announced today that Al Altomari, president and CEO of Agile, will be a featured panelist at the Biotech 2011 joint BioNJ & PA Bio meeting, the premier bioscience conference in the mid-Atlantic region. The panel, titled "Current Concepts in Financing: What are the Options?" will explore financing options for emerging biopharmaceutical companies on Tuesday, October 25th from 10:30 am to 11:45 am Eastern. The Biotech 2011 conference will be held at the Philadelphia Convention Center in Philadelphia from October 24th through 25th.
"The BioNJ and PA Bio organizations work diligently to continue to support innovation and emerging companies and have been a great support to Agile throughout the years as we continue to work to bring our lead product AG200-15 through the final stages, leading up to our planned 2012 submission to the FDA," said Al Altomari, president and CEO, Agile Therapeutics. "We appreciate the ongoing commitment of these organizations as we work to bring more convenient methods of hormonal contraceptives to women."
In mid-November, Agile Therapeutics will receive the New Jersey Technology Council's 2011 Life Science Company of the Year award. The NJTC Gala Awards is held annually to publicly recognize and celebrate some of New Jersey's upcoming and most successful companies.
Agile Therapeutics is a pharmaceutical development company specializing in women's healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company's lead product, AG200-15, is a once-weekly contraceptive patch currently in Phase III clinical trials. In addition, Agile is also developing a low-dose, progestin-only contraceptive patch, AG900. Both AG200-15 and AG900 incorporate proprietary transdermal delivery technology, Skinfusion™, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit .
Biotech 2011 is the premier bioscience conference in the mid-Atlantic region. Partnered by BioNJ and PA Bio, the event promotes collaboration, skill development, and networking among top executives from global pharmaceutical, biotech, medical device, and diagnostic companies; venture capitalists and other investors; university researchers; university-industry liaison officers; government officials; and support organizations. For more information, please visit .
Contact:
Laura Yoshida for Agile Therapeutics
212-867-1762
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.10.2011 - 05:01 Uhr
Sprache: Deutsch
News-ID 1049325
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PRINCETON, NJ
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 103 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Agile Therapeutics to Speak at Biotech 2011
"
steht unter der journalistisch-redaktionellen Verantwortung von
Agile Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
